title: Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.
abstract: OBJECTIVE
  To evaluate the effect of different human chorionic gonadotropin (hCG) doses on the ongoing pregnancy rates in patients with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective, randomized, controlled trial.
  
  
  METHODS
  Tertiary university referral center.
  
  
  METHODS
  Eighty PCOS patients.
  
  
  METHODS
  Patients were randomized to receive 10,000 IU (n = 28), 5000 IU (n = 26), or 2500 IU (n = 26) of hCG for triggering final oocyte maturation as soon as >or=3 or more follicles of 17 mm or larger were present at ultrasound. Patients were stimulated with recombinant follicle stimulating hormone (FSH) and daily gonadotropin-releasing hormone (GnRH) antagonist, starting on day 6 of stimulation.
  
  
  METHODS
  Ongoing pregnancy, fertilization rates.
  
  
  RESULTS
  The median fertilization rates were 52.8%, 65.4%, and 55.6% after administration of 10,000 IU, 5000 IU and 2500 IU, respectively. The ongoing pregnancy rates per PCOS patient receiving hCG were 26.9% (7 of 26), 30.8% (8 of 26) and 34.8% (8 of 23), respectively.
  
  
  CONCLUSIONS
  A decrease in the dose of hCG used to trigger final oocyte maturation does not appear to affect adversely the probability of pregnancy in PCOS patients treated by IVF using GnRH antagonists and recombinant FSH, and further testing in future larger-scale trials is recommended.
authors: Centre for Reproductive Medicine, Vrije Universiteit Brussel, Brussels, Belgium. stratis.kolibianakis@irg.gr
authors: Efstratios M
authors: EM
authors: Kolibianakis
authors: Evangelos G
authors: EG
authors: Papanikolaou
authors: Herman
authors: H
authors: Tournaye
authors: Michel
authors: M
authors: Camus
authors: Andre C
authors: AC
authors: Van Steirteghem
authors: Paul
authors: P
authors: Devroey
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000494:pharmacology / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000502:physiology; D006801:Humans; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D006063:Chorionic Gonadotropin; D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone